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In 2002, Dr Thomas Pickering and our group introduced the 
term masked hypertension (MHT)1 to describe individuals with 
normal clinic blood pressure (CBP) levels (<140/90 mm Hg) 
and ambulatory hypertension (awake ≥135/85 mm Hg). MHT 
is associated with increased left ventricular (LV) mass,2 a 
marker of cardiovascular end-organ damage, and an increased 
risk of cardiovascular disease (CVD) events, that is significantly 
more than in sustained normotension (clinic and ambulatory 
normotension).3–7 The confluence of increased CVD risk, a 
failure to be diagnosed by the conventional approach of blood 
pressure measurement in the clinic setting, and relatively high 
prevalence8–11 makes MHT a public health concern.
Epidemiologic studies have shown that CBP in the prehyper-
tension (PHT) range (i.e., mean systolic blood pressure (SBP) 
120–139 mm Hg or mean diastolic blood pressure (DBP) 
80–89 mm Hg) confer an increased CVD risk.12 PHT is asso-
ciated with higher levels of LV mass13 and also a higher risk 
of CVD events,12 compared to optimal blood pressure levels 
(<120/80 mm Hg).
Recent evidence suggests that CBP levels are significantly 
higher among individuals with MHT compared to individu-
als with sustained normotension,9 despite both groups hav-
ing CBP levels in the normal range (<140/90 mm Hg). These 
findings suggest that the prevalence of PHT may be dispro-
portionally higher in MHT than in sustained normotension, 
or alternatively that the prevalence of MHT may be higher 
in PHT than in those with optimal CBP. These hypotheses 
have not been directly examined in previous studies, particu-
larly when out-of-office blood pressure is determined by an 
ambulatory blood pressure (ABP) monitoring. Furthermore, 
the relative contributions of MHT and PHT to CVD risk are 
also unclear. The primary aim of this study was to evaluate the 
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Background
Masked hypertension (MHT) and prehypertension (PHT) are 
both associated with an increase in cardiovascular disease (CVD) 
risk, relative to sustained normotension. This study examined 
the diagnostic overlap between MHT and PHT, and their 
interrelationships with left ventricular (LV) mass index (LVMI), a 
marker of cardiovascular end-organ damage.
Methods
A research nurse performed three manual clinic blood pressure (CBP) 
measurements on three occasions over a 3-week period (total of nine 
readings, which were averaged) in 813 participants without treated 
hypertension from the Masked Hypertension Study, an ongoing 
worksite-based, population study. Twenty-four-hour ambulatory blood 
pressure (ABP) was assessed by using a SpaceLabs 90207 monitor. LVMI 
was determined by echocardiography in 784 (96.4%) participants.
results
Of the 813 participants, 769 (94.6%) had normal CBP levels 
(<140/90 mm Hg). One hundred and seventeen (15.2%) participants 
with normal CBP had MHT (normal CBP and mean awake ABP 
≥135/85 mm Hg) and 287 (37.3%) had PHT (mean CBP 120–
139/80–89 mm Hg). 83.8% of MHT participants had PHT and 34.1% 
of PHT participants had MHT. MHT was infrequent (3.9%) when CBP 
was optimal (<120/80 mm Hg). After adjusting for age, gender, body 
mass index (BMI), race/ethnicity, history of high cholesterol, history 
of diabetes, current smoking, family history of hypertension, and 
physical activity, compared with optimal CBP with MHT participants, 
LVMI was significantly greater in PHT without MHT participants and in 
PHT with MHT participants.
conclusions
In this community sample, there was substantial diagnostic overlap 
between MHT and PHT. The diagnosis of MHT using an ABP monitor 
may not be warranted for individuals with optimal CBP.
Keywords: ambulatory blood pressure monitoring; blood pressure; 
echocardiography; hypertension;
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degree of diagnostic overlap between MHT and PHT in a large 
community sample, and to secondarily investigate their inter-
relations with LV mass, a marker of cardiovascular end-organ 
damage.
Methods
Study population. The Masked Hypertension Study, an ongo-
ing population-based study of the prevalence, predictors, and 
prognosis of MHT, is comprised of employees recruited from 
Stony Brook University, University Hospital at Stony Brook, 
Columbia University Medical Center, and a private hedge 
fund management organization in New York. The current 
analysis includes 813 participants, enrolled between February 
2005 and August 2010; 2,381 were screened during this period. 
Participants were excluded if they were <18 years of age (n = 
176); taking antihypertensive or other medications that are 
known to affect blood pressure (n = 431); had a history of 
CVD or major arrhythmias including atrial fibrillation (n = 
17); had evidence of secondary hypertension other than a his-
tory of pregnancy-induced hypertension, chronic renal fail-
ure (creatinine >1.6 mg/dl), liver disease, adrenal disease, or 
thyroid disease (n = 28); had a screening clinic SBP >160 mm 
Hg or DBP >105 mm Hg (n = 18); pregnant (n = 13); work-
ing <20 h a week (n = 32); non-English speaking (n = 5); had 
active substance abuse or a severe debilitating psychiatric dis-
order (n = 7); or were not interested (n = 508), not available 
(n = 52), or dropped out before starting the study (n = 118). 
For our analysis, another 163 participants were excluded 
due to pending study visits or had dropped out during the 
study, resulting in available data from 813 participants. The 
blood pressure eligibility criterion for this study was chosen 
to obtain a sample with a wide distribution of untreated blood 
pressures. For safety reasons, we referred participants imme-
diately to their physicians for further management if their 
screening CBP was >160/105 mm Hg. Information about 
demographics, cardiovascular risk factors, and family history 
of hypertension were ascertained from participant interview. 
Written informed consent was obtained from all subjects. The 
study was approved by the Institutional Review Boards of 
Columbia University and Stony Brook University.
Study procedures. Participants attended five visits over a 4-week 
period. During the first 3 visits (visit 1–3), which occurred 
during a 3-week period, the participant was escorted into an 
examination room and asked to rest in the seated position for 
at least 5 min, after which a research nurse/technician obtained 
three CBP readings at 2-min intervals using a mercury sphyg-
momanometer and stethoscope.14 Arm circumference was 
measured, and appropriate-sized cuffs were utilized for blood 
pressure assessment.14 Thus, a total of nine CBP readings were 
available for each participant. On visit 3, the participant was 
fitted with an appropriate-sized arm cuff for a Spacelabs ABP 
monitor (ABPM) (Model 90207; Spacelabs, Redmond, WA). 
ABP measurements were taken at 28-min intervals through-
out the subsequent 24-h monitoring period. The recording was 
analyzed to obtain average awake and sleep SBP and DBP levels, 
based on sleep and awake times defined by data obtained from 
an actigraphy monitor worn on the wrist (ActiWatch; Phillips 
Respironics, Murrayville, PA), supplemented by diary reports 
of the times subjects woke up and went to sleep. During the 
awake period, participants wore a second actigraphy monitor 
on the waist (Actical; Phillips Respironics) to determine the 
level of physical activity.15
At visit 5, fasting blood samples were drawn from partici-
pants for determining total cholesterol, triglycerides, and high-
density lipoprotein cholesterol concentrations. The Friedewald 
equation was used to calculate low-density lipoprotein choles-
terol. M-mode, and two-dimensional echocardiograms were 
also performed and stored in a DICOM digital format for off-
line analysis. Echocardiographers blinded to patients’ clinical 
characteristics and blood pressure levels performed LV meas-
urements (LVIDd, LV internal diameter during diastole; IVSd, 
interventricular septal thickness during diastole; and PWTd, 
posterior wall thickness during diastole), according to the rec-
ommendations of the American Society of Echocardiography.16 
LV mass was calculated using the corrected American Society 
of Echocardiography method: 0.8 × (1.04 × ((IVSd + LVIDd + 
PWTd)3 – LVIDd3)) + 0.6. LV mass index (LVMI) was calcu-
lated by dividing LV mass by estimated body surface area. Of 
the 813 participants, 784 (96.4%) underwent the echocardio-
graphy examination and had images of sufficient quality for 
LVMI determination. Compared to participants with available 
LVMI data (N = 784), participants without available LVMI 
data (N = 29) were younger (39.8 ± 11.6 years vs. 45.3 ± 10.3 
years, P < 0.01) and had a greater body mass index (BMI) (36.6 
± 3.7 years vs. 27.5 ± 5.3 kg/m2, P < 0.01). There were no group 
differences in gender (P = 0.46), race (P = 0.40), and ethnicity 
(P = 0.97).
Hypertension categories defined by CBP and ABP. For the 
primary analysis, the nine CBP readings were used to esti-
mate mean CBP. Clinic hypertension was defined as a mean 
SBP ≥140 mm Hg or mean DBP ≥90 mm Hg. Ambulatory 
hypertension, based on mean awake ABP, was defined as mean 
SBP ≥135 mm Hg or mean DBP ≥85 mm Hg.14 Participants 
without clinic hypertension were categorized either as hav-
ing PHT, defined by mean SBP 120–139 mm Hg or mean 
DBP 80–89 mm Hg, or as having optimal blood pressure 
levels, defined by mean SBP <120 mm Hg and mean DBP 
<80 mm Hg.17 MHT was defined as having clinic normoten-
sion and ambulatory hypertension. Sustained hypertension 
was defined as having both clinic and ambulatory hyperten-
sion. Sustained normotension was defined by having both 
normal CBP and ABP levels. White coat hypertension was 
defined as having clinic hypertension without ambulatory 
hypertension.
The participants in whom LVMI was assessed were divided 
into three groups: optimal CBP and normal awake ABP, MHT, 
and/or PHT, and sustained hypertension. Participants in the 
MHT and/or PHT group were further divided into three 
subgroups: optimal CBP with MHT (mean CBP levels in the 
optimal range with ambulatory hypertension), PHT without 
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MHT (i.e., mean CBP levels in the PHT range and ambulatory 
normotension), and PHT with MHT (mean CBP levels in the 
PHT range and ambulatory hypertension).
Statistical analyses. Results are expressed as numbers, per-
centages, mean ± s.d., and/or adjusted mean ± s.e. The number 
and percentage of clinic normotensive participants with PHT 
and MHT was determined as was the prevalence of PHT in 
participants with sustained normotension. To address the sec-
ondary aim of the study, one-way analysis of variance was first 
used to assess group differences in LVMI. Participants with 
white coat hypertension were excluded from these analyses. 
Analysis of covariance was also used to evaluate LVMI dif-
ferences after adjusting for age, gender, BMI, race (African 
American or not), and ethnicity (Hispanic or not) (model 1). 
A second multivariable model (model 2) was estimated that 
additionally controlled for self-reported history of high cho-
lesterol (diagnosed by a physician), self-reported history of 
diabetes (diagnosed by a physician), current smoking status, 
family history of hypertension (including 1st degree relatives 
and/or grandparents), and physical activity (determined by 
the Actical monitor). Since most studies assess CBP at only 
one visit, we performed sensitivity analyses in which the three 
CBP readings from visit 1 were used to estimate mean CBP 
levels. Statistical analyses were performed using SPSS v.18.0 
(SPSS, Chicago, IL).
results
Table 1 shows the characteristics of the 813 study participants. 
Of the 44 participants with clinic hypertension based on the 
mean of 9 CBP readings, 36 (81.8%) had sustained hyperten-
sion and 8 (18.2%) had white coat hypertension. For both 
systolic and diastolic BP, CBP was significantly lower than 
awake ABP (P < 0.001).
diagnostic overlap between Mht and Pht in participants with 
normal cBP levels
Based on the mean of nine CBP readings, the correlation coef-
ficients between CBP and awake ABP were 0.75 (P < 0.001) 
and 0.64 (P < 0.001) for SBP and DBP, respectively. Of the 769 
participants with normal CBP levels, 652 (84.8%) had sus-
tained normotension and 117 (15.2%) had MHT; 287 (37.3%) 
had PHT. 98 participants had both MHT and PHT, constitut-
ing 83.8% (98/117) of those with MHT, and 34.1% (98/287) of 
those with PHT (Figure 1). The prevalence of PHT was higher 
among those with MHT (83.8%) than among those with sus-
tained normotension (29.0% = 189/652). Figure 2 shows the 
number and proportion with MHT by categories of normal 
CBP. The prevalence of MHT was higher in participants with 
CBP in the PHT range (34.1%) compared to those with opti-
mal CBP (3.9%). Although the number of participants with 
MHT was greater in the lower half of the PHT range (53 par-
ticipants in the lower half vs. 45 participants in the upper 
half), the proportional risk of MHT was higher in the upper 
half of the PHT range (51.7% in the upper half vs. 26.5% in 
the lower half).
differences in lVMi across blood pressure groups
Based on the mean of 9 CBP readings, 446 participants had 
optimal CBP and normal awake ABP, 295 had MHT and/or 
PHT, and 35 had sustained hypertension. Group differences 
were seen in age, gender, Hispanic ethnicity, BMI, history of 
high cholesterol, total cholesterol, triglycerides, high-density 
lipoprotein, low-density lipoprotein, CBP, and awake and sleep 
table 1 | characteristics of the masked hypertension study 
participants
Characteristics N = 813
Age, years 45.1 ± 10.4
Sex, % female 58.4
Race/ethnicity
 % Black or African-American 6.5
 % Hispanic 10.6
Body mass index, kg/m2 27.6 ± 5.3
History of high cholesterol, % 26.1
Total cholesterol, mg/dl 194 ± 37.9
Triglycerides, mg/dl 106.1 ± 73.1
HDL, mg/dl 58.4 ± 16.8
LDL, mg/dl 114.7 ± 33.9
History of diabetes, % 3.6
Current smoking, % 7.8
Family history of hypertension, % 64.1
Physical activity,a mean counts/min 267.8 ± 207.9
Clinic blood pressure (mean of nine readings)
 Systolic blood pressure, mm Hg 116.2 ± 11.6
 Diastolic blood pressure, mm Hg 75.4 ± 7.7
 % Hypertensiveb 5.4
 % Prehypertensivec 35.3
 % Optimald 59.3
Clinic blood pressure (mean of three readings)
 Systolic blood pressure, mm Hg 116.3 ± 13.0
 Diastolic blood pressure, mm Hg 76.0 ± 9.0
 % Hypertensiveb 8.9
 % Prehypertensivec 37.0
 % Optimald 54.1
Ambulatory blood pressure (mean awake)
 Systolic blood pressure, mm Hg 123.1 ± 10.3
 Diastolic blood pressure, mm Hg 77.4 ± 7.4
 % Hypertensivee 18.8
Ambulatory (mean sleep)
 Systolic blood pressure, mm Hg 106.2 ± 10.6
 Diastolic blood pressure, mm Hg 62.0 ± 7.8
 % Hypertensivef 18.9
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
a796 (97.9%) of the 813 participants had available mean physical activity data. bDefined 
by systolic blood pressure ≥140 or diastolic blood pressure ≥90 mm Hg. cDefined by 
systolic blood pressure 120–139 or diastolic blood pressure 80–89 mm Hg. dDefined 
by systolic blood pressure <120 and diastolic blood pressure <80 mm Hg. eDefined by 
systolic blood pressure ≥135 or diastolic blood pressure ≥85 mm Hg. fDefined by systolic 
blood pressure ≥120 or diastolic blood pressure ≥70 mm Hg.
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ABP (see Supplementary Table S1 online). There were sig-
nificant differences in LVMI across the three groups (Table 2, 
one-way analysis of variance, P < 0.001). Compared to partici-
pants with optimal CBP and normal awake ABP, LVMI was sig-
nificantly greater in participants with MHT and/or PHT (P < 
0.001) and in participants with sustained hypertension (P < 
0.001). LVMI was also significantly greater in sustained hyper-
tension participants compared to those with MHT and/or PHT 
(P < 0.01). These differences remained significant in adjusted 
models (models 1 and 2, Table 2).
Of the 295 participants in the MHT and/or PHT group, 18 
participants had optimal CBP with MHT, 180 had PHT with-
out MHT, and 97 had PHT with MHT. Differences in gender, 
BMI, CBP, and awake and sleep ABP were seen across these 
subgroups (Table 3). There were significant group differences 
in LVMI (Table 4, one-way analysis of variance, P < 0.001). 
Compared with optimal CBP with MHT participants, LVMI 
was significantly greater in PHT without MHT participants 
(P < 0.01) and in PHT with MHT participants (P < 0.001). 
LVMI was also significantly greater in PHT with MHT partici-
pants compared to PHT without MHT participants (P = 0.04). 
After adjustment for age, gender, BMI, race and ethnicity 
(model 1, Table 4), there was no longer a significant differ-
ence in LVMI between participants with PHT without MHT 
and PHT with MHT (P = 0.19). All other group differences 
remained significant. Results were similar after adjustment for 
additional covariates (model 2, Table 4).
sensitivity analyses
The pattern of results was similar when mean CBP was esti-
mated from three readings. Of the 72 participants with 
clinic hypertension based on the mean of three CBP read-
ings, 50 (69.4%) had sustained hypertension and 22 (30.6%) 
had white coat hypertension. For both systolic and diastolic 
table 2 | left ventricular mass index in participants with optimal 
cBP with normal awake aBP, Mht, and/or Pht, and sustained 
ht based on the mean of nine cBP readings
Optimal CBP 
with normal 






(N = 35) P value
P < 0.001  
(one-way 
ANOVA)
Unadjusted 59.0 ± 13.7 66.2 ± 15.3 73.3 ± 17.0 P1 < 0.001
P2 < 0.001
P3 < 0.01
P < 0.01  
(ANCOVA)
Model 1a 60.8 ± 0.7 64.0 ± 0.8 69.0 ± 2.3 P1 = 0.01
P2 < 0.01
P3 = 0.04
P < 0.001 
(ANCOVA)
Model 2b 60.8 ± 0.7 64.2 ± 0.8 69.2 ± 2.4 P1 < 0.01
P2 < 0.01
P3 = 0.045
Data are crude means ± s.d. (unadjusted model) or adjusted means ± s.e. (models 1 
and 2). P1 = comparison of optimal CBP with normal awake ABP vs. MHT and/or 
PHT. P2  = comparison of optimal CBP with normal awake ABP vs. sustained HT. P3 = 
comparison of MHT and/or PHT vs. sustained HT.
ABP, ambulatory blood pressure; ANCOVA, analysis of covariance; ANOVA, analysis of 
variance; CBP, clinic blood pressure; HT, hypertension; MHT, masked hypertension; PHT, 
prehypertension.
aModel 1 adjusts for age, sex, body mass index, race, and ethnicity. bModel 2 adjusts for 
covariates in model 1 + history of high cholesterol, history of diabetes, current smoking 
status, family history of hypertension, and physical activity.
189 98 19
Figure 1 | Diagnostic overlap between masked hypertension and 
prehypertension based on the mean of nine clinic blood pressure readings. 
Circle with solid line represent participants with masked hypertension. Circle 
with dotted line represent the participants with prehypertension. Of the 769 
participants with normal clinic blood pressure, a total of 117 participants 
had masked hypertension and 287 participants had prehypertension. 98 
participants had both masked hypertension (MHT) and prehypertension 
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Figure 2 | Distribution of masked hypertension across clinic blood pressure 
categories in the normal range (<140/90 mm Hg) based on the mean of nine 
readings. Clinic blood pressure levels in the normal range were categorized 
as follows: mean SBP ≥130 mm Hg or mean DBP ≥85 mm Hg (with mean SBP 
<140 mm Hg and mean DBP <90 mm Hg); mean SBP ≥120 mm Hg or mean 
DBP ≥80 mm Hg (with mean SBP <130 mm Hg and mean DBP <85 mm Hg); 
mean SBP ≥110 mm Hg or mean DBP ≥75 mm Hg (with mean SBP <120 mm 
Hg and mean DBP <80 mm Hg); mean SBP ≥100 mm Hg or mean DBP ≥70 mm 
Hg (with mean SBP <110 mm Hg and mean DBP <75 mm Hg); and mean SBP 
<100 mm Hg and mean DBP <70 mm Hg. Of the 769 participants with normal 
clinic blood pressure, a total of 287 participants had prehypertension and 
482 had optimal clinic blood pressure levels. The risk of masked hypertension 
was disproportionally concentrated among those participants with 
prehypertension. CBP, clinic blood pressure; DBP, diastolic blood pressure; 
MHT, masked hypertension; SBP, systolic blood pressure.
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BP, CBP was significantly lower than awake ABP (P < 0.001). 
Of the 741 participants with normal CBP levels, 638 (86.1%) 
had sustained normotension and 103 (13.9%) had MHT; 301 
(40.6%) had PHT. Supplementary Figure S1 online shows 
substantial diagnostic overlap between MHT and PHT. 
Furthermore, the prevalence of PHT was higher among those 
with MHT (75.7%) than among those with sustained normo-
tension (35.0% = 223/638). Supplementary Figure S2 online 
shows the number and proportion of MHT by categories of 
normal CBP. The prevalence of MHT was higher in partici-
pants with CBP in the PHT range (25.9%) compared to those 
with optimal CBP (5.7%).
Characteristics of participants with available LVMI by group 
(optimal CBP and normal awake ABP, MHT and/or PHT, and 
sustained hypertension) and subgroup (optimal CBP with 
MHT, PHT without MHT, and PHT with MHT) are presented 
in Supplementary Tables S2 and S3 online. Mean LVMI by 
group and subgroup are shown in Supplementary Tables S4 
and S5 online.
Finally, as nocturnal hypertension is associated with 
increased CVD risk,18 additional analyses were performed in 
which nocturnal hypertension (mean sleep ABP ≥120/70 mm 
Hg) was added to model 2 for the analyses in which mean CBP 
was estimated from nine readings. The relations across groups 
remained unchanged (data not shown). Nocturnal hyperten-
sion also had no impact on the individual relations of PHT 
and MHT with LVMI (interaction P = 0.99 between nocturnal 
hypertension and PHT, interaction P = 0.13 between noctur-
nal hypertension and MHT).
discussion
This study adds important information to the literature on 
MHT diagnosis. In our study, there were several principal find-
ings. There was substantial diagnostic overlap between MHT 
and PHT in clinic normotensive participants. The prevalence 
of MHT was relatively high in participants with PHT and low 
in participants with optimal CBP. Furthermore, the prevalence 
of PHT was greater in MHT than in sustained normotension.
table 3 | characteristics of participants who underwent echocardiographic assessment of left ventricular mass index and were 
classified as having optimal cBP with Mht, Pht without Mht, and Pht with Mht based on the mean of nine cBP readings
Characteristics
Optimal CBP with MHT 
(N = 18)
PHT without MHT PHT with MHT
P valuea(N = 180) (N = 97)
Age, years 44.7 ± 9.4 47.8 ± 10.4 48.4 ± 9.5 0.34
Sex, % female 72.2 52.2 34.0 <0.01
Race/ethnicity
 % Black 5.6 6.7 9.3 0.7
 % Hispanic 0.0 7.2 8.2 0.46
Body mass index, kg/m2 26.6 ± 5.8 30.1 ± 5.6 28.8 ± 4.8 0.01
History of high cholesterol, % 16.7 31.1 26.8 0.38
Total cholesterol, mg/dl 188.3 ± 39.3 198.8 ± 40.9 201.4 ± 41.9 0.47
Triglycerides, mg/dl 98.8 ± 53.5 121.6 ± 68.3 138.7 ± 118.3 0.12
HDL, mg/dl 62.3 ± 14.7 54.8 ± 17.4 52.9 ± 14.6 0.09
LDL, mg/dl 106.3 ± 36.7 119.6 ± 36.3 122.3 ± 37.9 0.24
History of diabetes, % 0.0 6.1 1.0 0.08
Current smoking, % 16.7 8.9 5.2 0.22
Family history of hypertension, % 72.2 70 63.9 0.54
Physical activity,b mean counts/min 374.1 ± 314.9 266.9 ± 239.5 254.9 ± 167.1 0.17
Clinic (mean)
 Systolic blood pressure, mm Hg 112.8 ± 4.5 124.4 ± 5.4 126.7 ± 6.2 <0.001
 Diastolic blood pressure, mm Hg 74.9 ± 3.0 80.0 ± 4.4 82.3 ± 4.4 <0.001
Ambulatory (mean awake)
 Systolic blood pressure, mm Hg 131.6 ± 5.9 125.4 ± 5.9 135.7 ± 7.2 <0.001
 Diastolic blood pressure, mm Hg 86.6 ± 4.1 77.5 ± 5.4 86.9 ± 4.6 <0.001
Ambulatory (mean sleep)
 Systolic blood pressure, mm Hg 110.0 ± 6.1 108.6 ± 8.5 116.5 ± 9.8 <0.001
 Diastolic blood pressure, mm Hg 66.2 ± 4.8 63.0 ± 6.2 69.7 ± 6.5 <0.001
ANOVA, analysis of variance; CBP, clinic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MHT, masked hypertension; PHT, prehypertension.
aOne-way ANOVA for continuous variables. χ2 for categorical variables. bOf the 784 participants who underwent echocardiography and had assessment of left ventricular mass index, 
767 (97.8%) had available mean physical activity. 0 (0%) of the 18 optimal CBP with MHT participants, 4 (2.2%) of the 180 PHT without MHT participants, and 5 (5.2%) of the 97 PHT with 
MHT participants did not have mean physical activity data.
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In the general population, especially in younger individuals 
with clinic normotension, awake ABP tends to be higher than 
CBP.19–22 We have hypothesized that as both CBP and ABP 
rise with aging, ABP first exceeds the threshold for a diagnosis 
of ambulatory hypertension while CBP increases but remains 
in the clinic normotensive range.20,23 As demonstrated by 
our study, a large proportion of these individuals have PHT. 
We posit that the CBP of these MHT individuals eventually 
crosses the threshold for clinic hypertension, leading to sus-
tained hypertension. This is supported by increasing evidence 
that MHT is a precursor for sustained hypertension.24–26
Of the MHT participants in our study, those with PHT (i.e., 
PHT with MHT) had significantly higher levels of LVMI than 
those with optimal CBP (i.e., optimal CBP with MHT). Given 
that ABP has superior predictive value for CVD risk over CBP, 
one would also anticipate that PHT with MHT would be a 
higher CVD risk category than PHT without MHT. However, 
although there was a significant unadjusted difference in 
LVMI between PHT with MHT and PHT without MHT par-
ticipants in our study, this difference was no longer significant 
in adjusted models. One possible explanation for this finding 
is the large number and high quality of CBP readings (aver-
age of nine readings taken on three separate occasions accord-
ing to published guidelines14) that were obtained and used to 
define mean CBP. The correlations between CBP and ABP in 
our study are greater than what has been observed in some 
previous studies,27,28 which may have limited the ability to 
detect differences in LVMI between PHT participants with and 
without MHT. Presently, scarce data exist from prior studies 
as to whether MHT adds prognostic information in individu-
als with PHT. In what to our knowledge is the only published 
study to examine the predictive value of MHT for CVD events 
in participants with PHT, Pierdomenico et al.29 found that in 
participants with PHT, MHT was associated with a signifi-
cantly higher rate of CVD events, compared to those partici-
pants without MHT (“true PHT”). This study was limited by 
a small number of events (18 events in MHT and PHT vs. 11 
events in true PHT) and potentially incomplete examination 
of confounders such as male gender.29
Also, unexpectedly in our study, compared to participants 
with optimal CBP with MHT, LVMI was significantly greater 
in participants with PHT without MHT in adjusted models. 
In addition to the number and quality of CBP readings, which 
likely increased the predictive value of CBP, there are other 
plausible explanations for these findings. First, notably, as it 
is relatively rare for an individual with optimal CBP to have 
MHT, the sample size of the optimal CBP with MHT group 
was small. Additionally, variability in ABPM30 may have also 
allowed for some participants with optimal CBP and normal 
awake ABP to be incorrectly categorized as having optimal 
CBP and ambulatory hypertension, leading to a lower than 
expected LVMI in the optimal CBP with MHT group.
These issues have important clinical implications. If MHT is 
a high-risk subgroup of the larger PHT group, then it may be 
appropriate to recommend that individuals with PHT receive 
targeted screening for MHT using ABPM. Furthermore, if 
optimal CBP with MHT is a lower CVD risk group, then 
ABPM may not be indicated for individuals with optimal CBP 
levels, particularly as the prevalence of MHT is low in this 
group.
Whether our results on the diagnostic overlap between MHT 
and PHT can be extended to home blood pressure monitor-
ing is unknown. Findings from the Self measurement of blood 
pressure at Home in the Elderly: Assessment and Follow-up 
(SHEAF) study31, the Japan Home vs. Office BP Measurement 
Evaluation (J-HOME) study32, and a substudy of the Three-
City Study (3C)33 indicate that clinic SBP in the PHT range 
is associated with MHT, when determined by home blood 
pressure monitoring. These findings may not be directly com-
parable to the results of our study. In addition to the reliance 
on home blood pressure monitoring, these studies included 
treated hypertensive patients. Further, participants were older, 
and many had prevalent CVD.
There are several possible limitations to our study. First, as 
awake ABP was estimated from one 24-h monitoring period, 
we cannot exclude the possibility that the study results would 
have differed with the inclusion of additional 24-h period. 
Multiple, high quality readings were used in our study to 
estimate CBP. Nonetheless, this approach is consistent with 
published guidelines, which recommend the performance 
table 4 | left ventricular mass index in participants with optimal 
cBP with Mht, Pht without Mht, and Pht with Mht based on 
the mean of nine cBP readings
Optimal CBP  
with MHT
PHT without 
MHT PHT with  
MHT (N = 97) P value(N = 18) (N = 180)











P = 0.01 
(ANCOVA)
Model 2b 57.3 ± 3.4 66.1 ± 1.1 68.6 ± 1.5 P1 = 0.01
P2 < 0.01
P3 = 0.19
Data are crude means ± s.d. (unadjusted model) or adjusted means ± s.e. (models 1 
and 2). P1 = comparison of Optimal CBP with MHT vs. PHT without MHT. P2 = comparison 
of Optimal CBP with MHT vs. PHT with MHT. P3 = comparison of PHT without MHT vs. 
PHT with MHT.
ANCOVA, analysis of covariance; ANOVA, analysis of variance; CBP, clinic blood pressure; 
MHT, masked hypertension; PHT, prehypertension.
aModel 1 adjusts for age, sex, body mass index, race, and ethnicity. bModel 2 adjusts for 
covariates in model 1 + history of high cholesterol, history of diabetes, current smoking 
status, family history of hypertension, and physical activity.
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of measurements in this manner to estimate CBP.14 Finally, 
our sample consisted of adult employees who were generally 
healthy. Whether our results can be extended to other popula-
tions remains unknown.
Major strengths of the study include a large sample size, the 
inclusion of a large proportion of participants with normal CBP 
levels, the exclusion of participants on antihypertensive medica-
tions, and consideration of several possible confounding factors 
including physical activity. Further, echocardiography with the 
assessment of LVMI was successfully performed in almost all 
participants. Finally, as this is one of the first studies to directly 
examine the degree of diagnostic overlap between MHT and 
PHT in a community sample, and to investigate their respective 
relationships with a marker of cardiovascular end-organ dam-
age, the current study provides valuable new information.
In conclusion, the results of the present study demonstrate 
that in an employed, community sample, there is substantial 
diagnostic overlap between MHT and PHT in individuals 
with clinic normotension. Furthermore, given the low preva-
lence of MHT in individuals with optimal CBP, our findings 
suggest that the diagnosis of MHT using an ABPM may not 
be warranted for individuals with optimal CBP. Future stud-
ies should confirm our findings, and additionally examine the 
relative contributions of PHT and MHT to CVD event risk.
Supplementary material is linked to the online version of the paper at http://
www.nature.com/ajh
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